Chemical Information
Antiviral agent ID	DrugRepV_4367
Antiviral agent name	2-(1,3-benzodioxol-5-yl)-1-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazole
IUPAC Name	2-(1,3-benzodioxol-5-yl)-1-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazole
SMILES (canonical)	C1OC2=C(O1)C=C(C=C2)CN3C4=CC=CC=C4N=C3C5=CC6=C(C=C5)OCO6
Molecular Formula	C22H16N2O4
Molecular Weight (g/mol)	372.4
InChl	InChI=1S/C22H16N2O4/c1-2-4-17-16(3-1)23-22(15-6-8-19-21(10-15)28-13-26-19)24(17)11-14-5-7-18-20(9-14)27-12-25-18/h1-10H,11-13H2
Structural Information
Clinical Information
Biological Information
Secondary Indication	Ebola virus (EBOV) NA GP, amino acids 196 to 205
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	293FT
Secondary Indication (Viral titer)	1 μM
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Drug concentration)	40 μM
Secondary Indication (Cell based assay)	CatL-Peptide cleavage
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	Percentage inhibition [ -15.9 % ]
Reference	Elshabrawy HA, Fan J, Haddad CS, Ratia K, Broder CC, Caffrey M, Prabhakar BS..Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay..J Virol. 2014 Apr;88(8):4353-65. doi: 10.1128/JVI.03050-13. Epub 2014 Feb 5. PubMed Central PMCID: P PMID:24501399
Comment	A novel broad-spectrum small molecule that could block cathepsin L-mediated cleavage was identified and thus inhibit the entry of pseudotypes bearing the glycoprotein derived from SARS-CoV or Ebola, Hendra, or Nipah virus. The small molecule can be further optimized and developed into a potent broad-spectrum antiviral drug.